SCHEMBL6200425

SCHEMBL6200425

COC(=O)C1(c2ccccc2)CCN(C2CCN(Cc3ccccc3)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
OPRL1 P41146 2/20 0.53
OPRM1 P35372 1/20 0.53
RECQL P46063 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ACHE P22303 1/20 0.51
KMT2A Q03164 1/20 0.49
CHRM4 P08173 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5764547 0.91 KDM4E (0.51) KDM4EALDH1A1OPRL1OPRM1RECQL
SCHEMBL5764552 0.91 KDM4E (0.51) KDM4EALDH1A1OPRL1OPRM1RECQL
SCHEMBL6746046 0.88 KDM4E (0.60) KDM4EALDH1A1OPRL1OPRM1NPSR1
Hydrochloric Acid SCHEMBL7091076 0.84 HRH3 (0.46) KDM4EALDH1A1KMT2ACHRM4NPSR1
SCHEMBL6194958 0.81 OPRL1 (0.52) OPRL1OPRM1
SCHEMBL10567213 0.81 OPRM1 (0.53) KDM4EALDH1A1OPRL1OPRM1NPSR1
SCHEMBL26637780 0.78 GAA (0.49) KDM4EALDH1A1OPRL1OPRM1KMT2A
SCHEMBL4881599 0.77 L3MBTL1 (0.60) KDM4EALDH1A1SMN1; SMN2NPSR1
Hydrochloric Acid SCHEMBL6495374 0.76 HTR1D (0.53) KDM4EALDH1A1OPRL1RECQLSMN1; SMN2
Hydrochloric Acid SCHEMBL5765402 0.76 HTR1D (0.53) KDM4EALDH1A1OPRL1RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1021185-A4 DIDHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMA CORP (US) 2005-09-07 EP disclosed
US-20020010186-A1 Dihydropyrimidines and uses thereof SYNAPTIC PHARMACEUTICAL CORPORATION 2002-01-24 US disclosed
US-6245773-B1 BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE SYNAPTIC PHARMACEUTICAL CORPORATION 2001-06-12 US disclosed
EP-1021185-A1 DIDHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2000-07-26 EP disclosed
WO-1998051311-A2 DIHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-11-19 WO disclosed
WO-1997042956-A1 DIDHYDROPYRIMIDINES AND USES THEREOF SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010186-A1 Dihydropyrimidines and uses thereof QDPR, DPYD, ADRA1D KDM4E 3005/4885ALDH1A1 63/4885OPRL1 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.